Entrada Therapeutics, Inc. (NASDAQ:TRDA) Given Average Recommendation of “Hold” by Analysts

Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) have earned a consensus rating of “Hold” from the six research firms that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $17.50.

TRDA has been the subject of a number of recent research reports. Roth Capital set a $10.00 price objective on shares of Entrada Therapeutics in a research note on Friday, May 8th. Wall Street Zen cut Entrada Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 28th. Weiss Ratings downgraded Entrada Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a report on Thursday, June 11th. Guggenheim reduced their price target on Entrada Therapeutics from $20.00 to $17.00 and set a “buy” rating for the company in a research report on Monday, June 8th. Finally, HC Wainwright downgraded Entrada Therapeutics from a “buy” rating to a “neutral” rating in a research report on Friday, May 8th.

Insiders Place Their Bets

In other news, Director Bernhardt G. Zeiher acquired 5,000 shares of the business’s stock in a transaction dated Wednesday, May 20th. The shares were purchased at an average price of $5.86 per share, with a total value of $29,300.00. Following the transaction, the director directly owned 5,000 shares in the company, valued at approximately $29,300. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Nathan J. Dowden sold 15,000 shares of the business’s stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $15.33, for a total transaction of $229,950.00. Following the transaction, the chief operating officer owned 198,588 shares of the company’s stock, valued at approximately $3,044,354.04. This trade represents a 7.02% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 9.49% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Entrada Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. State of Wyoming increased its position in shares of Entrada Therapeutics by 130.9% during the second quarter. State of Wyoming now owns 7,575 shares of the company’s stock worth $51,000 after purchasing an additional 4,295 shares in the last quarter. Russell Investments Group Ltd. lifted its holdings in shares of Entrada Therapeutics by 72.7% during the 3rd quarter. Russell Investments Group Ltd. now owns 8,808 shares of the company’s stock valued at $51,000 after purchasing an additional 3,707 shares during the last quarter. Occudo Quantitative Strategies LP acquired a new stake in shares of Entrada Therapeutics in the 2nd quarter worth $68,000. IHT Wealth Management LLC purchased a new position in Entrada Therapeutics during the 2nd quarter worth $72,000. Finally, Jain Global LLC acquired a new position in Entrada Therapeutics during the 3rd quarter valued at about $69,000. Hedge funds and other institutional investors own 86.39% of the company’s stock.

Entrada Therapeutics Stock Performance

NASDAQ TRDA opened at $6.80 on Friday. The company has a market capitalization of $263.98 million, a price-to-earnings ratio of -1.70 and a beta of -0.26. The company’s 50-day simple moving average is $7.05 and its two-hundred day simple moving average is $10.19. Entrada Therapeutics has a one year low of $4.93 and a one year high of $16.45.

Entrada Therapeutics (NASDAQ:TRDA) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.95) earnings per share for the quarter, topping the consensus estimate of ($1.06) by $0.11. Entrada Therapeutics had a negative net margin of 2,895.05% and a negative return on equity of 51.22%. The firm had revenue of $0.88 million during the quarter, compared to analysts’ expectations of $2.92 million. Equities analysts expect that Entrada Therapeutics will post -4.12 earnings per share for the current fiscal year.

About Entrada Therapeutics

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.